STOCK TITAN

Immunovant director Atul Pande sells 3,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Immunovant, Inc. (IMVT) director Atul Pande exercised 3,000 fully vested stock options at an $8.43 exercise price on November 11, 2026, acquired 3,000 common shares and sold 3,000 shares at $36.00 each. The transactions were pursuant to a Rule 10b5-1 Plan adopted December 26, 2025. The report lists 62,181 stock options following the exercise and 20,000 common shares held indirectly by trust.

Insider Pande Atul
Role Director
Sold 3,000 shs ($108K)
Approx. gross sale proceeds $108K
Approx. exercise cost $25K
Approx. pre-tax spread $83K
Share of Position Sold 2.5%
Type Security Shares Price Value
Exercise Stock Option (right to buy) F1, F2 3,000 $0.00 $0.00
Exercise Common Stock F1 3,000 $8.43 $25K
Sale Common Stock F1 3,000 $36.00 $108K
Holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 62,181 options (Direct); Common Stock — 116,731 shares (Direct); Common Stock — 20,000 shares (Indirect, By Trust)
Holdings Before and After: Stock Option (right to buy), 65,181 to 62,181 options (Direct); Common Stock, 116,731 to 116,731 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (2)
  1. F1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
  2. F2. Reflects an award of stock options to purchase Common Shares that is fully vested.
Stock options exercised 3,000 options November 11, 2026; fully vested award
Exercise price $8.43 per share Exercise of 3,000 stock options on November 11, 2026
Common shares acquired 3,000 shares Acquired upon option exercise on November 11, 2026
Common shares sold 3,000 shares Sale on November 11, 2026
Sale price $36.00 per share Sale of 3,000 common shares on November 11, 2026
Stock options following exercise 62,181 options Reported following the November 11, 2026 exercise
Common shares held indirectly by trust 20,000 shares Reported indirect holding by trust
Rule 10b5-1 Plan regulatory
"transactions pursuant to a Rule 10b5-1 Plan adopted December 26, 2025"
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
exercise price financial
"exercised stock options at an $8.43 exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IMVT shares did director Atul Pande sell, and at what price?

Atul Pande sold 3,000 common shares at $36.00 per share on November 11, 2026. He exercised 3,000 fully vested stock options at an $8.43 exercise price to acquire the shares; the transactions were pursuant to a Rule 10b5-1 Plan adopted December 26, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Pande Atul

(Last)(First)(Middle)
C/O IMMUNOVANT, INC.
1000 PARK FORTY PLAZA, SUITE 210

(Street)
DURHAM NORTH CAROLINA 27713

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Immunovant, Inc. [ IMVT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/11/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/11/2026M(1)3,000A$8.43119,731D
Common Stock11/11/2026S(1)3,000D$36116,731D
Common Stock20,000IBy Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$8.4311/11/2026M(1)3,000 (2)11/19/2029Common Stock3,000$062,181D
Explanation of Responses:
1. Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on December 26, 2025.
2. Reflects an award of stock options to purchase Common Shares that is fully vested.
Remarks:
/s/ Tiago Girao, attorney-in-fact for Atul Pande11/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading